SCHEMBL21531009

SCHEMBL21531009

O=S(=O)(Cl)c1nc[nH]c1Br

nearest known ligand 0.31

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.31
CSNK2A2 P19784 1/20 0.31
RAB9A P51151 1/20 0.31
CSNK2B P67870 1/20 0.31
CSNK2A1 P68400 1/20 0.31
KMT2A Q03164 1/20 0.31
DYRK1A Q13627 1/20 0.31
CSNK2A3 Q8NEV1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28321212 0.76 CYP1A2 (0.41) MEN1CSNK2A2RAB9ACSNK2BCSNK2A1
SCHEMBL392946 0.64
SCHEMBL27256530 0.62 PDPK1 (0.32) ALDH1A1HSD17B10TDP1
SCHEMBL937654 0.61 TRPV4 (0.39) MEN1RAB9AKMT2AALDH1A1HSD17B10
SCHEMBL25846913 0.60 GABRR1 (0.39) ALDH1A1TDP1
SCHEMBL16363472 0.58 CA12 (0.38)
SCHEMBL1464993 0.58 S1PR1 (0.37) MEN1KMT2ADYRK1AALDH1A1HSD17B10
SCHEMBL25726659 0.58 ALDH1A1 (0.30) ALDH1A1HSD17B10TDP1
SCHEMBL27174827 0.58 ALDH1A1 (0.30) ALDH1A1HSD17B10TDP1
SCHEMBL31631668 0.58 GABRR1 (0.37) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3571187-B1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH INC (US) 2023-11-22 EP disclosed
US-11702428-B2 Chemical compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2023-07-18 US disclosed
US-11702428-B2 Chemical compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2023-07-18 US disclosed
US-11702428-B2 Chemical compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2023-07-18 US disclosed
US-20220306649-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2022-09-29 US disclosed
US-20210395268-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2021-12-23 US disclosed
EP-3851434-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY Genentech, Inc. (US) 2021-07-21 EP disclosed
US-11040985-B2 Chemical compounds as inhibitors of interleukin-1 activity GENENTECH, INC. (US) 2021-06-22 US disclosed
US-20190337965-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY GENENTECH, INC. (US) 2019-11-07 US disclosed
CN-110366549-A Compound as interleukin-1 activity inhibitor 基因泰克公司 2019-10-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337965-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 MEN1 4064/4885CSNK2A2 4183/4885RAB9A 2686/4885
US-20210395268-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 MEN1 4064/4885CSNK2A2 4183/4885RAB9A 2686/4885
US-11040985-B2 Chemical compounds as inhibitors of interleukin-1 activity IL1B, IL1A, IL18 MEN1 4064/4885CSNK2A2 4183/4885RAB9A 2686/4885
US-11702428-B2 Chemical compounds as inhibitors of interleukin-1 activity IL1B, IL1A, IL18 MEN1 4064/4885CSNK2A2 4183/4885RAB9A 2686/4885
US-20220306649-A1 CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY IL1B, IL1A, IL18 MEN1 4064/4885CSNK2A2 4183/4885RAB9A 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.